NDATRANSDERMALSYSTEM
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CATAPRES-TTS-3 (clonidine transdermal system) by Lavipharm is adrenergic alpha2-agonists [moa]. Approved for central alpha-2 adrenergic agonist [epc]. First approved in 1984.
Drug data last refreshed Yesterday
Mechanism of Action
Adrenergic alpha2-Agonists
Pharmacologic Class:
Central alpha-2 Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Lavipharm
France - Paris
Worked on CATAPRES-TTS-3 at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.